Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1677/joe.0.0330211 | DOI Listing |
Similar Publications
Preparation, In Vivo and Molecular Docking Study of Nano-Emulsion Obtained from the Isolated Phytoconstituents of Symplocos racemosa for Mitigating Depression.
Chem Biodivers
March 2025
Noida Institute of Engineering and Technology Pharmacy Institute, Department of Pharmacology, Plot No.19, Knowledge Park-II, Greater Noida, INDIA.
Background: Depression is a prevalent, chronic, and debilitating disorder characterized by high treatment resistance. Symplocos racemosa, containing phenols and triterpenoids, acts as an antidepressant by elevating brain monoamine levels.
Objectives: This study aimed to enhance the targeted delivery of S.
Anti-Stress Effects of Berk. Enzymatic Extracts: A Preclinical Study.
Nutrients
March 2025
College of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea.
Chronic stress disrupts neurochemical balance, triggers inflammation, and compromises neuronal integrity, contributing to the development of stress-related disorders. This study aimed to evaluate the preventative effects of Berk (TF) enzymatic extracts on chronic restraint stress (CRS)-induced behavioral, neurochemical, and inflammatory dysfunctions in mice. Male C57BL/6N mice were administered TF at doses of 50 mg/kg and 100 mg/kg daily via oral gavage for 21 days during CRS exposure.
View Article and Find Full Text PDFRevealing Lingonberry's Neuroprotective Potential in Alzheimer's Disease Through Network Pharmacology and Molecular Docking.
Int J Mol Sci
March 2025
Department of Biochemistry and Molecular Biology, School of Basic Medicine, Harbin Medical University, Harbin 150086, China.
Alzheimer's disease is a progressive neurodegenerative disorder with limited treatment options. Lingonberry ( L.) has demonstrated neuroprotective and anti-inflammatory properties, yet the underlying mechanisms remain unclear.
View Article and Find Full Text PDFTowards Imaging Tau Hyperphosphorylation: Is DYRK1A a Potential Target for Imaging Hyperphosphorylation of Tau? Molecular Modeling Assessment and Synthesis of [I]Radioiodinated DYRK1A Inhibitor.
Molecules
February 2025
Preclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.
Dual specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A), a phosphorylation kinase, is localized within the central nervous system and is linked to hyperphosphorylation of Tau. Imaging of DYRK1A may provide an earlier biomarker for Tauopathies, including Alzheimer's disease (AD). We have used Chimera-Autodock to evaluate potential molecules for binding to the binding site of DYRK1A.
View Article and Find Full Text PDFTreatment options for depression in Parkinson's disease: a mini-review.
Int Clin Psychopharmacol
March 2025
Oasi Research Institute - IRCCS, Troina, Italy.
Depression is a common comorbidity in Parkinson's disease (PD), significantly reducing patients' quality of life. This mini-review examines pharmacological and nonpharmacological therapies for managing depression in PD, analyzing their benefits, and limitations. Pharmacological options include tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), levodopa, dopaminergic agonists, and monoamine oxidase B inhibitors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.